Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q3 2014 · 10-Q
Revenue—
Net Income-$6.08M-$6.08MN/M vs Q3 2013 EPS Diluted-$0.21-$0.21N/M vs Q3 2013 Operating Income-$7,044,911N/M Operating Cash Flowderived-$4,239,314—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,261,749— ended Sep 30, 2014 · filed Oct 31, 2014 · 31 d after period end